Amphastar Pharmaceuticals, Inc.
AMPH
$27.23
-$0.35-1.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.20% | 11.83% | 18.80% | 20.16% | 19.01% |
| Total Other Revenue | -101.08% | -97.16% | -92.43% | -62.56% | 46.56% |
| Total Revenue | -0.03% | 1.37% | 8.05% | 13.59% | 20.33% |
| Cost of Revenue | 7.66% | 12.15% | 17.10% | 23.24% | 24.86% |
| Gross Profit | -6.86% | -7.56% | 0.44% | 5.66% | 16.57% |
| SG&A Expenses | 36.08% | 12.62% | 14.72% | 17.57% | 24.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.58% | 12.01% | 15.35% | 18.40% | 21.91% |
| Operating Income | -30.02% | -20.97% | -7.97% | 2.87% | 16.74% |
| Income Before Tax | -27.09% | -19.73% | -6.06% | 11.70% | 9.62% |
| Income Tax Expenses | -15.18% | -22.73% | 6.56% | -6.79% | -17.72% |
| Earnings from Continuing Operations | -29.22% | -19.10% | -8.44% | 15.98% | 16.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.22% | -19.10% | -8.44% | 15.98% | 16.58% |
| EBIT | -30.02% | -20.97% | -7.97% | 2.87% | 16.74% |
| EBITDA | -22.83% | -15.89% | -3.04% | 8.69% | 23.91% |
| EPS Basic | -27.66% | -18.10% | -8.46% | 15.72% | 16.54% |
| Normalized Basic EPS | -25.41% | -18.66% | -6.07% | 9.67% | 7.81% |
| EPS Diluted | -24.93% | -14.98% | -4.84% | 18.13% | 17.86% |
| Normalized Diluted EPS | -22.65% | -15.50% | -2.55% | 12.21% | 8.67% |
| Average Basic Shares Outstanding | -2.40% | -1.34% | -0.07% | 0.34% | 0.15% |
| Average Diluted Shares Outstanding | -6.16% | -5.10% | -3.73% | -1.78% | -0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |